Impact of high‐dose vitamin C on the mortality, severity, and duration of hospital stay in COVID‐19 patients: A meta‐analysis

Bhowmik, Khokon Kanti; Barek, Md. Abdul; Aziz, Abdul; Islam, Mohammad Safiqul

doi:10.1002/hsr2.762

Cited by 6 publications

(8 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth noting that in 2021 some authors were more optimistic about the role of vitamin C in the treatment of COVID-19, especially in terms of shortening the stay in the ICU department [ 60 ]. Similarly, meta-analysis from 2022 (August) highlighted the importance of vitamin C in COVID-19, emphasizing the reduction of mortality risk among COVID-19 patients (OR = 0.54, 95%CI = 0.42–0.69, p < 0.00001) and indicating that patients who consumed vitamin C showed lower risk of severe COVID-19 than those who did not take vitamin C (OR = 0.63, 95%CI = 0.43–0.94, p = 0.02) [ 61 ]. Due to the low risk associated with an increased supply of vitamin C, from the public health point of view, its administration should at least be considered [ 62 ].…”

Section: Discussionmentioning

confidence: 99%

Vitamin C Supplementation for the Treatment of COVID-19: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe respiratory syndrome coronavirus 2 (SARS-CoV-2), millions of people have died, and the medical system has faced significant difficulties. Our purpose was to perform a meta-analysis to estimate the effect of vitamin C on in-hospital mortality and the ICU or hospital length of stay for patients diagnosed with COVID-19. We conducted a systematic review with meta-analysis in the following databases: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials. We included studies that evaluated the effect of vitamin C supplementation, compared with standard treatment in COVID-19 patients who are ≥18 y of age. Nineteen trials were included in the meta-analysis. In-hospital mortality with and without vitamin C supplementation was 24.1% vs. 33.9% (OR = 0.59; 95%CI: 0.37 to 0.95; p = 0.03), respectively. Sub-analysis showed that, in randomized clinical trials, in-hospital mortality varied and amounted to 23.9% vs. 35.8% (OR = 0.44; 95%CI: 0.25 to 0.76; p = 0.003), respectively. In the non-randomized trials, in-hospital mortality was 24.2% vs. 33.5% (OR = 0.72; 95%CI: 0.38 to 1.39; p = 0.33), respectively. The ICU length of stay was longer in patients treated with vitamin C vs. standard therapy, 11.1 (7.3) vs. 8.3 (4.7) days (MD = 1.91; 95%CI: 0.89 to 2.93; p < 0.001), respectively. Acute kidney injury in patients treated with and without vitamin C varied and amounted to 27.8% vs. 45.0% (OR = 0.56; 95%CI: 0.40 to 0.78; p < 0.001), respectively. There were no differences in the frequency of other adverse events among patients’ treatment with and without vitamin C (all p > 0.05). The use of vitamin C reduces hospital mortality. The length of stay in the ICU is longer among patients treated with vitamin C. In terms of patient safety, vitamin C has an acceptable profile. Low doses of vitamin C are effective and safe. Despite some evidence of the usefulness of vitamin C in modifying the course of COVID-19, it is too early to modify guidelines and recommendations. Further studies, in particular randomized clinical trials, are necessary.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitamin C Supplementation for the Treatment of COVID-19: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…HIVC also protect against severe COVID-19 by decreasing the rates of mechanical ventilation and cardiac arrest in hospitalized severe patients [ 156 ]. Vitamin C consumption significantly reduces mortality risk with COVID-19 patients [ 157 ]. Furthermore, HIVC in combination with other drugs such as giammonium glycyrrhizinate, decreased the incidence rate of ARDS in COVID-19 patients [ 158 ].…”

Section: Therapeutic Agents Targeting Endothelial Dysfunction In Covi...mentioning

confidence: 99%

Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

2022

View full text Add to dashboard Cite

The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is still raging. However, the pathophysiology of acute and post-acute manifestations of COVID-19 (long COVID-19) is understudied. Endothelial cells are sentinels lining the innermost layer of blood vessel that gatekeep micro- and macro-vascular health by sensing pathogen/danger signals and secreting vasoactive molecules. SARS-CoV-2 infection primarily affects the pulmonary system, but accumulating evidence suggests that it also affects the pan-vasculature in the extrapulmonary systems by directly (via virus infection) or indirectly (via cytokine storm), causing endothelial dysfunction (endotheliitis, endothelialitis and endotheliopathy) and multi-organ injury. Mounting evidence suggests that SARS-CoV-2 infection leads to multiple instances of endothelial dysfunction, including reduced nitric oxide (NO) bioavailability, oxidative stress, endothelial injury, glycocalyx/barrier disruption, hyperpermeability, inflammation/leukocyte adhesion, senescence, endothelial-to-mesenchymal transition (EndoMT), hypercoagulability, thrombosis and many others. Thus, COVID-19 is deemed as a (micro)vascular and endothelial disease. Of translational relevance, several candidate drugs which are endothelial protective have been shown to improve clinical manifestations of COVID-19 patients. The purpose of this review is to provide a latest summary of biomarkers associated with endothelial cell activation in COVID-19 and offer mechanistic insights into the molecular basis of endothelial activation/dysfunction in macro- and micro-vasculature of COVID-19 patients. We envisage further development of cellular models and suitable animal models mimicking endothelial dysfunction aspect of COVID-19 being able to accelerate the discovery of new drugs targeting endothelial dysfunction in pan-vasculature from COVID-19 patients.

show abstract

“…Several meta-analyses are available which calculated the effect of especially high dose (mostly intravenous) vitamin C supplementation/therapy on clinical outcomes in (hospitalized) COVID-19 patients [ 90 , 143 , 144 , 145 , 146 , 147 , 148 , 149 ] ( Table 2 ).…”

Section: Selected Nutrients and Covid-19mentioning

confidence: 99%

The Role of Diet and Specific Nutrients during the COVID-19 Pandemic: What Have We Learned over the Last Three Years?

Rust

Ekmekçioğlu

2023

IJERPH

View full text Add to dashboard Cite

Nutrients and diets have an important impact on our immune system and infection risk and a huge number of papers have been published dealing with various aspects of nutrition in relation to SARS-CoV-2 infection risk or COVID-19 severity. This narrative review aims to give an update on this association and tries to summarize some of the most important findings after three years of pandemic. The analysis of major studies and systematic reviews leads to the conclusion that a healthy plant-based diet reduces the risks for SARS-CoV-2 infection and especially COVID-19 severity. Regarding micronutrients, vitamin D is to the fore, but also zinc, vitamin C and, to some extent, selenium may play a role in COVID-19. Furthermore, omega-3-fatty acids with their anti-inflammatory effects also deserve attention. Therefore, a major aim of societal nutritional efforts in future should be to foster a high quality plant-based diet, which not only exerts beneficial effects on the immune system but also reduces the risk for non-communicable diseases such as type 2 diabetes or obesity which are also primary risk factors for worse COVID-19 outcomes. Another aim should be to focus on a good supply of critical immune-effective nutrients, such as vitamin D and zinc.

show abstract

Impact of high‐dose vitamin C on the mortality, severity, and duration of hospital stay in COVID‐19 patients: A meta‐analysis

Cited by 6 publications

References 69 publications

Vitamin C Supplementation for the Treatment of COVID-19: A Systematic Review and Meta-Analysis

Vitamin C Supplementation for the Treatment of COVID-19: A Systematic Review and Meta-Analysis

Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

The Role of Diet and Specific Nutrients during the COVID-19 Pandemic: What Have We Learned over the Last Three Years?

Contact Info

Product

Resources

About